# Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

> **NCT00101894** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 119 (actual)

## Conditions studied

- Rectal Cancer
- Colon Cancer

## Interventions

- **DRUG:** FOLFOX-4
- **DRUG:** AMG 706
- **BIOLOGICAL:** Panitumumab (Part 1a only)
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT00101894
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2010-04
- **Final completion:** 2011-12
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2012-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101894, "Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00101894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*